FOLD · As filed with the SEC

Amicus Therapeutics balance sheet, by quarter

The statement as Amicus Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

Consolidated Balance Sheets · USD thousands

USD thousands	Q4 2025 Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025
Assets
Current assets:
Cash and cash equivalents	214,010	190,553	158,702	181,657
Investments in marketable securities	79,526	73,290	72,296	68,916
Accounts receivable, net	115,307	113,838	105,849	88,323
Inventories, net	228,819	177,928	154,875	132,412
Prepaid expenses and other current assets	38,511	38,457	46,285	39,491
Total current assets	676,173	594,066	538,007	510,799
Operating lease right-of-use assets, net	21,138	21,549	21,988	22,138
Property and equipment, less accumulated depreciation of $31,821 and $28,775 at December 31, 2025 and 2024, respectively	27,108	27,759	28,570	28,718
Intangible assets, less accumulated amortization of $9,085 and $5,802 at December 31, 2025 and 2024, respectively	13,915	14,743	15,570	16,389
Goodwill	197,797	197,797	197,797	197,797
Other non-current assets	13,739	12,897	13,371	13,998
Total Assets	949,870	868,811	815,303	789,839
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	28,630	19,103	13,893	14,451
Accrued expenses and other current liabilities	200,457	171,165	145,144	129,877
Operating lease liabilities	8,741	8,662	8,610	8,562
Total current liabilities	237,828	198,930	167,647	152,890
Long-term debt	392,660	391,985	391,322	390,708
Operating lease liabilities	40,962	42,174	43,383	44,196
Other non-current liabilities	4,179	5,298	8,647	8,487
Total liabilities	675,629	638,387	610,999	596,281
Stockholders' equity:
Common stock, $0.01 par value, 500,000,000 shares authorized, 310,853,963 and 299,041,653 shares issued and outstanding at December 31, 2025 and 2024, respectively	3,037	3,017	3,016	3,016
Common stock in treasury, at cost; 7,390 shares as of December 31, 2025	(71)	(71)	(71)	(71)
Additional paid-in capital	3,014,456	2,973,625	2,956,839	2,939,673
Accumulated other comprehensive gain (loss):
Foreign currency translation adjustment	24,120	22,886	30,935	12,941
Unrealized loss on available-for-sale securities	(11)	(53)	(129)	(135)
Warrants	0	0	0	0
Accumulated deficit	(2,767,290)	(2,768,980)	(2,786,286)	(2,761,866)
Total stockholders' equity	274,241	230,424	204,304	193,558
Total Liabilities and Stockholders' Equity	949,870	868,811	815,303	789,839

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.